NCT02536794View on ClinicalTrials.gov

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 14, 2016

Primary Completion Date

February 6, 2020

Study Completion Date

January 22, 2021

Conditions
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu NegativeRecurrent Breast CarcinomaStage IV Breast Cancer
Interventions
BIOLOGICAL

Anti-B7H1 Monoclonal Antibody MEDI4736

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (2)

60045

Northwestern University- Lake Forest Hospital, Lake Forest

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

MedImmune LLC
All Listed Sponsors
collaborator

MedImmune LLC

INDUSTRY

collaborator

Avon Breast Cancer Foundation

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER